RADX
No price yet
Announcements
Nothing here yet
Daily updates
- Radiopharm Theranostics reported positive Phase 2b results for 18F-RAD101 in recurrent brain metastasesSep 16, 2026
- Radiopharm's Phase 1 RAD301 imaging study showed favorable safety and tumor uptake in pancreatic cancerSep 10, 2026
- RAD202 Phase 1 study received clearance to escalate dosing to 180 mCiAug 21, 2026
- RAD202 Phase 1 study received clearance to escalate dosing to 180 mCiAug 20, 2026
FDA designations
Nothing here yet
News
- Radiopharm Theranostics dosed the first patient in the second cohort of its Phase 1/2a trial of BetaBart in B7-H3-expressing solid tumorsAug 26, 2026
- Radiopharm Theranostics received a positive recommendation from the Data Safety Monitoring Committee to advance to Cohort 4 of the Phase 1 HEAT trial of 177Lu-RAD202Aug 20, 2026
- Radiopharm Theranostics will meet with the U.S. FDA to align on the pivotal Phase 3 trial design for RAD 101 in diagnosing brain metastasesAug 17, 2026
- Radiopharm Theranostics reports positive Phase 2b results for RAD 101 in diagnosing brain metastasesJul 22, 2026
- Radiopharm Theranostics reports a durable partial response in the ongoing Phase 1 trial of RAD204Jul 22, 2026